Provided by Tiger Fintech (Singapore) Pte. Ltd.

Theratechnologies Inc.

2.62
-0.0411-1.55%
Volume:1.38M
Turnover:3.68M
Market Cap:120.42M
PE:-34.86
High:2.79
Open:2.51
Low:2.50
Close:2.66
Loading ...

Company Profile

Company Name:
Theratechnologies Inc.
Exchange:
NASDAQ
Establishment Date:
1993
Employees:
103
Office Location:
2015 Peel Street,11th Floor,Montreal,Quebec,Canada
Zip Code:
H3A 1T8
Fax:
514-331-9691
Introduction:
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Directors

Name
Position
Luc Tanguay
Director, President and Chief Executive Officer
Paul Pommier
Chairman of the Board
Gerald A. Lacoste
Director
Gilles Cloutier
Director
Jean Denis Talon
Director

Shareholders

Name
Position
Luc Tanguay
Director, President and Chief Executive Officer
Christian Marsolais
Senior Vice President, Scientific Affairs and Alliances
Jocelyn Lafond
Vice President, Legal Affairs, and Corporate Secretary
Marie Noel Colussi
Vice President, Finance
Pierre Perazzelli
Vice President, Pharmaceutical Development